Skip to main content

Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  268.12
-4.14 (-1.52%)
AAPL  301.55
-3.36 (-1.10%)
AMD  481.39
+7.07 (1.49%)
BAC  64.80
+0.80 (1.24%)
GOOG  342.49
-0.51 (-0.15%)
META  580.15
-18.97 (-3.17%)
MSFT  494.08
-9.73 (-1.93%)
NVDA  223.24
+5.74 (2.64%)
ORCL  153.03
+7.55 (5.19%)
TSLA  327.14
-5.67 (-1.70%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.